%0 Journal Article
%T Prognostic Significance of MET Amplification and Expression in Gastric Cancer: A Systematic Review with Meta-Analysis
%A Zhi Peng
%A Yan Zhu
%A Qianqian Wang
%A Jing Gao
%A Yilin Li
%A Yanyan Li
%A Sai Ge
%A Lin Shen
%J PLOS ONE
%D 2014
%I Public Library of Science (PLoS)
%R 10.1371/journal.pone.0084502
%X Background and Aims MET, the hepatocyte growth factor receptor, is a receptor tyrosine kinase overexpressed and activated in a subset of gastric cancer. Several studies investigated the relationship between MET amplification and expression with the clinical outcome in patients with gastric cancer, but yielded conflicting results. We performed a systematic review and meta-analysis to determine the influence of MET amplification and expression on prognosis in gastric cancer. Methods MEDLINE and EMBASE were searched for studies that explored the association between MET amplification and expression with survival in patients with gastric cancer up to 1 April, 2013. Data of individual hazard ratios (HRs) and 95% confidence intervals (CIs) for meta-analyses were extracted from the publications and combined in pooled HRs. Results Fourteen studies involving 2,258 patients with gastric cancer were included. It was suggested that MET overexpression had an unfavorable impact on survival of patients with gastric cancer, with HRs (95% CIs) of 2.57 (95% CI: 1.97¨C3.35) overall, 2.82 (95% CI: 1.86¨C4.27) among studies using amplification for measure scale of MET and 2.42 (95% CI: 1.66¨C3.54) for expression. The magnitude of association was reduced whereas remained statistically significant in high quality studies or in larger sample size studies and corresponding HRs were 2.18(1.76, 2.70) and 2.35(1.93, 2.87), respectively, without significant heterogeneity. Conclusion The findings from present study indicated that higher MET gene amplification and expression in gastric cancer was an indicator of poor prognosis.
%U http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0084502